ALPS Medical Breakthroughs ETF (SBIO) Declines 1.59% for Oct 2

October 2, 2018 - By Ash

Oct 2 is a negative day so far for ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) as the ETF is active during the day after losing 1.59% to hit $37.769 per share. The exchange traded fund has 278.41M net assets and 1.95% volatility this month.

Over the course of the day 45,840 shares traded hands, as compared to an average volume of 36,030 over the last 30 days for ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO).

The ETF is -1.56% of its 52-Week High and 51.95% of its low, and is currently having ATR of 0.76. This year’s performance is 11.68% while this quarter’s performance is 7.42%.

The ETF’s YTD performance is 18.02%, the 1 year is 27.53% and the 3 year is 6.13%.

The ETF’s average P/E ratio is 14.38, the price to book is 3.91, the price to sales is 5.46 and the price to cashflow is 8.68. It was started on 12/31/2014. The fund’s top holdings are: Ligand Pharmaceuticals Inc for 3.53% of assets, United Therapeutics Corp for 3.42%, Galapagos NV ADR for 3.29%, FibroGen Inc for 3.26%, Loxo Oncology Inc for 3.25%, Agios Pharmaceuticals Inc for 2.97%, Immunomedics Inc for 2.86%, Taro Pharmaceutical Industries Ltd for 2.71%, Hutchison China Meditech Ltd ADR for 2.48%, Endo International PLC for 2.45%. The ETF sector weights are: Basic Materials 0.00%, Consumer Cyclical 0.00%, Financial Services 0.00%, Realestate 0.00%, Consumer Defensive 0.00%, Healthcare 100.00%, Utilities 0.00%, Communication Services 0.00%, Energy 0.00%, Industrials 0.00%, Technology 0.00%. The ETF currently as 1.69% yield.

More news for ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) were recently published by: Nasdaq.com, which released: “Best ETFs for 2018: Don’t Sweat This Quarter for the SBIO ETF” on September 28, 2018. Investorplace.com‘s article titled: “10 ETFs to Buy for a Rally” and published on September 06, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>